These functionally different cell populations in tumor justify the need of combining immune therapy in cholangiocarcinoma, and PNOC and LAIR2 could be clinical biomarkers for patient evaluation before immune therapy, predicting patients’ survival and tumor immune infiltration accordingly. The gene discussed is LAIR2; the disease is neoplasm.